双歧杆菌及其制剂对炎症性肠病作用机制研究进展  

Progress in Understanding the Action Mechanism of Bifidobacterium and Its Preparations in Inflammatory Bowel Disease

作　　者：杨硕 唐宗馨 段勃帆 陈禹含 郭欢新 孟祥晨[1] YANG Shuo;TANG Zongxin;DUAN Bofan;CHEN Yuhan;GUO Huanxin;MENG Xiangchen(Key Laboratory of Dairy Science,Ministry of Education,School of Food Science,Northeast Agricultural University,Harbin 150030,China)

机构地区：[1]东北农业大学食品学院,乳品科学教育部重点实验室,黑龙江哈尔滨150030

出　　处：《食品科学》2023年第5期275-281,共7页Food Science

基　　金：“十三五”国家重点研发计划重点专项(2017YFD0400304)。

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)是一种发病机制尚未明确且容易反复性发作的胃肠道炎症疾病。随着生活环境和饮食习惯等的改变,IBD的全球发病率已达0.3%,并在日益增长。一直以来IBD的治疗方法聚焦在抗炎药物以及肠道免疫调节方面,近年来随着对肠道微生物研究的深入,发现炎症性肠道疾病的发生与肠道菌群的变化有着密切的关联,同时还发现一部分微生物可以从多方面缓解IBD。本文对肠道有益菌群——双歧杆菌及其制剂在IBD中的应用以及作用机制进行了综述,以期为通过益生菌治疗IBD提供参考。Inflammatory bowel disease(IBD)is an inflammatory disease of the gastrointestinal tract whose pathogenesis is not yet clear and it tends to recurrent.The global prevalence of IBD has reached 0.3%and is increasing as a result of changes in living environment and dietary habits.Current treatments for IBD focus on anti-inflammatory drugs and intestinal immunomodulatory therapy,and recent studies on intestinal microorganisms have shown that the occurrence of IBD is closely related to changes in the intestinal flora and some intestinal microorganisms can alleviate IBD in various ways.In this paper,we review the application and action mechanism of the probiotic intestinal bacterium Bifidobacterium and its preparations in IBD treatment,expecting to provide a reference for the treatment of IBD by probiotics.

关 键 词：炎症性肠病 双歧杆菌 肠道菌群 应用 作用机制 

分 类 号：TS201.4[轻工技术与工程—食品科学]